Safety monitoring and information
Understand the ways we work to ensure medicines and medical devices remain as safe and effective as possible. Access information on product safety topics.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
What safety means
Safety is determined by weighing the known and potential risks, against the expected benefits when a therapeutic good is used as intended. While some risks are identified during the approval process, others may only become apparent after broader use.
The safety of therapeutic goods is a shared responsibility between regulators, sponsors, healthcare professionals and consumers.
How we monitor safety
We monitor safety through a range of different activities:
- Pre-market evaluation: Products must meet strict safety, quality and efficacy standards before being included in the Australian Register of Therapeutic Goods (ARTG).
- Post-market surveillance: We monitor products once they are on the market through adverse event reports, product testing, recalls and safety reviews.
- Adverse event reporting: Anyone can report adverse events or side effects, product defects or safety concerns. These reports help identify emerging risks and inform regulatory action.
- Product testing and investigations: Our laboratories test therapeutic goods to ensure they meet Australian standards and compare results with international benchmarks. See further information on our Product testing and investigations.
- Recalls and market actions: If a safety issue is identified, we may initiate recalls, issue safety alerts or require product corrections.
A key activity in safety monitoring is identifying patterns that emerge when problems are reported by sponsors, health professionals and consumers. An adverse event occurring does not necessarily mean that there is something wrong with a therapeutic good. However, each report helps to build a picture of the safety profile of a product. You can Report an adverse event or safety problem.
Latest alerts
-
Product correction: Ypsomed Australia is reminding users to ensure they use a compatible smart device and operating system (OS) when using the Mylife CamAPS FX app.
-
Phytologic Holdings Pty Ltd is recalling one batch of Henry Blooms Infant Liquid D3 & K2 with Probiotic due to a dosing syringe error.
-
We are aware of the recent report of a death of a child overseas. The death has been found to have been caused by a fire that occurred during the use of a hyperbaric chamber device.
Latest articles
-
What’s changed on the website
We have made changes to our website to make finding information easier. These improvements are based on your feedback. -
Product Information safety updates - October 2025
Information for health professionals about medicines with safety related updates to their Product Information. -
New warning on hepatotoxicity risk for Veoza (fezolinetant)
New warnings on hepatotoxicity risk and monitoring recommendations have been added to the Product Information for Veoza (fezolinetant).
Latest publications
-
Communique from the 10th meeting of the WHPWG, 17 July 2025
-
Advisory Committee on Vaccines meeting statement 53
-
Communique from the 9th meeting of the WHPWG 27 March 2025
Open consultations
-
Survey: Digital Mental Health Tools
Survey on digital mental health tools.